Intended for healthcare professionals


GSK recalls ranitidine products over potential carcinogen contamination

BMJ 2019; 367 doi: (Published 08 October 2019) Cite this as: BMJ 2019;367:l5933
  1. Elisabeth Mahase
  1. The BMJ

Pharmacies should stop dispensing four prescription ranitidine products supplied by GlaxoSmithKline (GSK) and should return any stock to the company, says an alert issued by the UK Medicines and Healthcare Products Regulatory Agency (MHRA).1

The alert said that the recall was a “precautionary measure” owing to the products potentially being contaminated with an impurity, N-nitrosodimethylamine (NDMA), which has been identified as a potential carcinogen.

But it also told doctors to advise patients not to stop taking their …

View Full Text

Log in

Log in through your institution


* For online subscription